Seizure control after late introduction of anakinra in a patient with adult onset Rasmussen’s encephalitis
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Epilepsy & Behavior Reports
- Vol. 16, 100462
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsyNeurobiology of Disease, 2013
- Rasmussen encephalitis treated with natalizumabNeurology, 2013
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- Seizure‐induced brain‐borne inflammation sustains seizure recurrence and blood–brain barrier damageAnnals of Neurology, 2012
- IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizuresBrain, Behavior, and Immunity, 2011
- A case of Rasmussen encephalitis treated with rituximabNature Reviews Neurology, 2009
- Antagonism of peripheral inflammation reduces the severity of status epilepticusNeurobiology of Disease, 2009
- Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: A European consensus statementBrain, 2005
- Interleukin‐1β contributes to the generation of experimental febrile seizuresAnnals of Neurology, 2004
- Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in miceProceedings of the National Academy of Sciences, 2000